Table 1.
Characteristics of patients with (group I) and without (group II) primary liver carcinoma and helicobacter PCR results
| Patient | Sex | Age (years) | Liver pathology | Serological markers | Helicobacter PCR results | ||||||
| HBV-M | Anti-HCV | 16S rRNA | 26 kDa | cagA | vacA | glmM | rps4 | ||||
| Group 1 | |||||||||||
| 1 | M | 32 | HCC and mild fibrosis | HBsAg+, HBcAb+ | – | + | + | + | – | + | – |
| 2 | M | 41 | HCC and cirrhosis | HBsAb+, HBeAb+, HBcAb+ | – | – | – | – | – | – | – |
| 3 | M | 34 | HCC and mild fibrosis | HBsAb+, HBeAb+, HBcAb+ | – | + | + | – | – | – | – |
| 4 | M | 35 | HCC | HBsAb+ | – | + | + | + | – | – | – |
| 5 | M | 38 | HCC and cirrhosis | HBsAb+, HBeAg+, HBcAb+ | – | – | – | – | – | – | – |
| 6 | M | 29 | HCC | HBsAg+, HBcAb+ | – | – | – | – | – | – | – |
| 7 | M | 55 | HCC and cirrhosis | HBsAb+, HBeAb+, HBcAb+ | – | + | + | – | – | – | – |
| 8 | F | 58 | HCC and cirrhosis | HBsAg+, HBcAb+ | – | – | – | – | – | – | – |
| 9 | M | 54 | HCC and cirrhosis | HBsAb+, HBeAb+, HBcAb+ | – | – | – | – | – | – | – |
| 10 | M | 64 | HCC and cirrhosis | HBsAg+, HBcAb+ | – | + | + | – | – | – | – |
| 11 | M | 37 | HCC and mild fibrosis | HBsAg+, HBcAb+ | – | + | + | – | – | – | – |
| 12 | M | 35 | HCC and cirrhosis | HBsAb+, HBeAg+, HBcAb+ | – | – | – | – | – | – | – |
| 13 | M | 36 | HCC and mild fibrosis | HBsAg+, HBcAb+ | – | – | – | – | – | – | – |
| 14 | M | 42 | HCC and cirrhosis | HBsAb+, HBeAg+, HBcAb+ | – | – | – | – | – | – | – |
| 15 | F | 60 | HCC and cirrhosis | HBsAb+, HBeAg+, HBcAb+ | – | – | – | – | – | – | – |
| 16 | M | 37 | HCC and mild fibrosis | HBsAg+, HBcAb+ | – | + | + | – | – | + | – |
| 17 | M | 58 | HCC and cirrhosis | HBsAg+, HBcAb+ | – | – | – | – | – | – | – |
| 18 | M | 34 | HCC and mild fibrosis | HBsAb+, HBeAg+, HBcAb+ | – | – | – | – | – | – | – |
| 19 | M | 35 | HCC | HBsAb+ | – | + | – | – | – | – | – |
| 20 | M | 32 | HCC | HBsAb+ | – | – | – | – | – | – | – |
| Group II | |||||||||||
| 1 | M | 38 | Cholelithiasis | – | – | – | – | – | – | – | – |
| 2 | F | 28 | Haemangioma | – | ND | – | – | – | – | – | – |
| 3 | M | 41 | Cholelithiasis | – | – | – | – | – | – | – | – |
| 4 | M | 39 | Cholelithiasis | – | – | – | – | – | – | – | – |
| 5 | M | 25 | Haemangioma | – | – | – | – | – | – | – | – |
| 6 | M | 34 | Cholelithiasis | – | – | – | – | – | – | – | – |
| 7 | F | 54 | Haemangioma | – | – | – | – | – | – | – | – |
| 8 | F | 45 | Cholelithiasis | – | ND | – | – | – | – | – | – |
| 9 | M | 36 | Haemangioma | – | – | – | – | – | – | – | – |
| 10 | F | 26 | Hepatic cyst | – | – | – | – | – | – | – | – |
| 11 | M | 45 | Haemangioma | – | – | – | – | – | – | – | – |
| 12 | M | 34 | Hepatic cyst | – | ND | – | – | – | – | – | – |
| 13 | M | 29 | Cholelithiasis | – | – | – | – | – | – | – | – |
| 14 | F | 32 | Haemangioma | – | – | – | – | – | – | – | – |
| 15 | F | 47 | Cholelithiasis | – | – | – | – | – | – | – | – |
| 16 | M | 27 | Cholelithiasis | – | – | – | – | – | – | – | – |
HBV-M, hepatitis B virus marker; HBcAb, antibody to hepatitis B core antigen; HBeAb, antibody to hepatitis B e antigen; HBeAg, hepatitis B e antigen; HBsAb, antibody to hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ND, not done; PCR, polymerase chain reaction.